Answers are grounded in this paper and cite their sources.
Neuroblastoma is the most frequent extracranial solid tumor of childhood. In 7 out of 10 cases, neuroblastoma is already disseminated at the time of diagnosis. Of the current nuclear medicine techniques, scintigraphy with methaiodobenzylguanidine, which is a 123 I-labeled noradrenaline analog or ( 123 I-MIBG), plays the most important role in the evaluation of neuroblastoma. Currently, a new PET-tracer, 18 F-MFBG ( 18 F-labeled benziguanidine analog), has emerged that can be used in the radionuclide diagnosis of neuroblastomas. Our clinical observations showed identical diagnostic efficiency to scintigraphy data with 123 I-MIBG with significantly faster blood clearance than 123 I-MIBG, which allows us to perform studies as early as 1 h after intravenous administration. In one case PET/CT with 18 F-MIBG revealed additional tumor foci, which allowed to correct therapy, which is certainly of great importance in clinical practice.
No takes yet. Share an insight, caveat, or question.
Крылов et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: